fidaxomicin + Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Clostridium Difficile-Associated Diarrhea (CDAD)
Conditions
Clostridium Difficile-Associated Diarrhea (CDAD)
Trial Timeline
Oct 10, 2012 → Apr 16, 2015
NCT ID
NCT01691248About fidaxomicin + Placebo
fidaxomicin + Placebo is a phase 3 stage product being developed by Merck for Clostridium Difficile-Associated Diarrhea (CDAD). The current trial status is completed. This product is registered under clinical trial identifier NCT01691248. Target conditions include Clostridium Difficile-Associated Diarrhea (CDAD).
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01691248 | Phase 3 | Completed |
Competing Products
20 competing products in Clostridium Difficile-Associated Diarrhea (CDAD)